Neovascular Age-Related Macular Degeneration
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Diagnosis of type 1, 2, and 3 MNV confirmed by OCTA/OCT, in accordance with international nAMD diagnostic criteria. 2.Presence of active disease, as evidenced by subretinal/intraretinal fluid or hemorrhage on OCT. 3.Treatment with a single, exclusive anti-VEGF agent (conbercept) via intravitreal injection at the hospital. 4.All patients were treatment-naïve.
Exclusion criteria
Exclusion criteria: 1.Ocular Conditions:Maculopathy from causes other than MNV: pathologic myopia, traumatic CNV, angioid streaks, central serous chorioretinopathy.Advanced irreversible damage: Extensive macular atrophy or fibrosis, disruption of outer retinal layers on OCT, significant vitreous hemorrhage, or cataract affecting OCTA image quality.Other fundus diseases: Coexisting diabetic retinopathy (with DME), retinal vein occlusion (RVO), glaucoma (cup-to-disc ratio > 0.8), or optic neuropathy. 2.Systemic Conditions:Systemic health risks: Uncontrolled hypertension (>160/100 mmHg), diabetes mellitus (HbA1c > 8%), or a recent (within 6 months) cardiocerebrovascular event (e.g., myocardial infarction, stroke). 3.Drug Contraindications or Allergies:Allergy to conbercept or any component of anti-VEGF drugs.Long-term use of anticoagulant therapy (e.g., warfarin) with an INR > 3.0. 4.Treatment History:Recent ocular treatments: Previous vitrectomy, macular laser, or PDT therapy within 3 months. 5. Pregnancy or Lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CMT; | — |
Secondary
| Measure | Time frame |
|---|---|
| SCP-VD; | — |
Countries
China
Contacts
Nanchong Hospital, Affiliated to Beijing Anzhen Hospital, Capital Medical University